NEW YORK, March 4 (GenomeWeb News) - US-based genomics-tool companies and drug makers eager to expand their footprint in Japan can take part in a week-long business-partnering program in Japan sponsored by the Japanese government.
Held on May 15-21 in
Many genomic-tool companies in the
"The investment climate in
"Many obstacles to foreign investment have been removed. Land prices, public utility charges, labor costs, interest rates and taxes have decreased, which has generated increased returns for investment and strengthened
Companies from various industries are scheduled to participate, including Japanese biomedical concerns, including Amano Enzyme, Fujisawa Pharmaceutical, Japan Tissue Engineering, Japan Tobacco, Meito Sangyo, Mitsubishi Chemical, Otsuka Pharmaceutical, Sanwa Chemical, Suzuken, Taiwa Pharmaceutical, Takara Bio, Tokai Medical Products, Toyobo, Asahi Kasei, Chugai Pharmaceuticals, Daiichi Pharmaceutical, Eisai, Kyowa Hakko, Summit Pharmaceuticals International, Takeda Pharmaceutical, and Yamanouchi Pharmaceutical.
The program includes sessions on market assessment, business reforms, and recent regulatory changes.
Additional information about the meeting can be found here.